Immix Biopharma Announces Phase 2 NEXICART‑2 Results — 89% CR

What Happened

• On September 29, 2026, Immix Biopharma (IMMX) announced in an 8‑K and press release that its CAR‑T candidate NXC‑201 produced an 89% complete response (CR) rate (40/45) across all 45 relapsed/refractory light‑chain (AL) amyloidosis patients in the Phase 2 NEXICART‑2 trial, as assessed by an independent review committee. The company said all 25 newly enrolled relapsed/refractory patients are either in CR or are already minimum residual disease (MRD)‑negative. Safety through August 4, 2026 was generally consistent with prior reports; no neurotoxicity or enterocolitis has been observed to date.

Key Details

• 89% CR rate: 40 of 45 patients achieved complete response (independent review).
• 25 new relapsed/refractory patients: all are CR or MRD‑negative; four pending patients are already MRD‑negative.
• Potential higher CR rate: Company notes MRD‑negativity in the four pending patients could raise CR to 98% (44/45).
• Trial status & timeline: NEXICART‑2 is fully enrolled (45 patients), registrational Phase 2 design; final readout and BLA submission planned mid‑2027.
• Safety: No relapses reported among patients who reached CR or MRD‑negativity; no neurotoxicity or enterocolitis observed.

Why It Matters

• These results, if confirmed and accepted by regulators, support the company’s planned BLA pathway and could materially affect Immix’s clinical and commercial prospects because AL amyloidosis is a serious, hard‑to‑treat condition with limited options. The high CR rate and MRD‑negativity are clinically meaningful endpoints often used in regulatory decisions for hematologic diseases. However, the filing also includes forward‑looking statements and cautions that timelines, future CR conversion, regulatory outcomes, and ultimate clinical benefit are subject to risks and uncertainties. Investors should note this is Phase 2 data, the company’s planned mid‑2027 milestones are projections, and future events (regulatory review, confirmatory data) will determine ultimate value.